Table 6.
Summary of gender, age and antivenom use in individual facilities
| Location | Age group | Total patients | AA1 | NA2 |
|---|---|---|---|---|
| Kabarnet | 1-15 | 20 | 8(40.00%) | 12(60.00%) |
| 16-30 | 8 | 3(37.50%) | 5 (62.50%) | |
| 31-45 | 4 | 0 (0.00%) | 4(100.00%) | |
| Over 45 | 5 | 2(40.00%) | 3 (60.00%) | |
| Total | 37 | 13(35.14%) | 24(64.86%) | |
| Kakamega | 1-15 | 27 | 8 (29.63%) | 19(70.37%) |
| 16-30 | 31 | 9 (29.03%) | 22(70.97%) | |
| 31-45 | 12 | 4 (33.33%) | 8 (66.67%) | |
| Over 45 | 7 | 2 (28.57%) | 5 (71.43%) | |
| Total | 77 | 23(29.87%) | 54(70.13%) | |
| Kapenguria | 1-15 | 7 | 4 (57.14%) | 3 (42.86%) |
| 16-30 | 2 | 2(100.00%) | 0 (0.00%) | |
| 31-45 | 1 | 1(100.00%) | 0 (0.00%) | |
| Over 45 | 4 | 3 (75.00%) | 1 (25.00%) | |
| Total | 14 | 10(71.43%) | 4 (28.57%) | |
| Makueni | 1-15 | 19 | 2 (10.53%) | 17(89.47%) |
| 16-30 | 15 | 1 (6.67%) | 14(93.33%) | |
| 31-45 Over 45 |
7 7 |
0 (0.00%) 0 (0.00%) |
7(100.00%) 7 (100%) |
|
| Total | 48 | 3 (6.25%) | 45(93.75%) |
1
Antivenom administered
2
Antivenom not administered